• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/18/25 4:52:57 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    false 0001860742 Bausch and Lomb Corporation 0001860742 2025-06-18 2025-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    June 18, 2025

    Date of Report (Date of the earliest event reported)

     

     

     

    Bausch + Lomb Corporation

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Canada   001-41380   98-1613662

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    520 Applewood Crescent

    Vaughan, Ontario

    Canada L4K 4B4

    (Address of Principal Executive Offices)(Zip Code)

     

    (905) 695-7700

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Shares, No Par Value   BLCO   New York Stock Exchange, Toronto Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 8.01   Other Events.

     

    Secured Notes Offering

     

    On June 18, 2025, Bausch + Lomb Corporation (the “Company” or “Bausch + Lomb”) announced that its subsidiaries, Bausch & Lomb Incorporated, a New York corporation (the “U.S. Co-Issuer”), and Bausch+Lomb Netherlands B.V. a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (the “Dutch Co-Issuer” and, together with U.S. Co-Issuer, the “Issuers”), priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (“Notes”). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof.

     

    As previously announced, the Company is also seeking to partially refinance its credit agreement, whereby the Company intends to obtain a $2.325 billion new term B loan facility (the “New Term B Loan Facility”) and a new $800 million revolving credit facility (the “New Revolving Credit Facility”). The New Term B Loan is expected to accrue interest at a rate of Term SOFR + 4.25% per annum. The allocated size of the New Term B Loan Facility was increased from the previously announced $2.2 billion. The Company intends to use the net proceeds from the Notes offering and the New Term B Loan Facility to repay in full the outstanding borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans due 2027 and to pay related fees and expenses.

     

    The closing of the Notes offering is not contingent upon the closing of the New Term B Loan Facility or the New Revolving Credit Facility.

     

    The Notes will be guaranteed by the Company and each of the Company’s subsidiaries (other than the Issuers) that are guarantors under the Company’s credit agreement and will be secured on a first priority basis by liens on the same assets that secure the obligations under the Company’s credit agreement and the Company’s 8.375% senior secured notes due 2028.

     

    Closing of the Notes offering is expected to occur on June 26, 2025, subject to customary closing conditions.

     

    The Notes are being offered in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

     

    The New Term B Loan Facility and New Revolving Credit Facility are also expected to close on June 26, 2025; however, there can be no assurances that the Company will be able to complete the New Term B Loan Facility and/or New Revolving Credit Facility transactions on the terms described above or at all. 

     

    The Company also issued a press release pursuant to Rule 135c under the Securities Act relating to the offering of the Notes. In accordance with Rule 135c(d) under the Securities Act, a copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

     

    The foregoing is qualified by reference to the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

     

    This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

     

     

     

    Item 9.01   Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit 

    Number 

      Description
         
    99.1   Press Release of Bausch + Lomb Corporation, announcing the pricing of the Notes offering, dated June 18, 2025
         
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BAUSCH + LOMB CORPORATION
         
         
      By: /s/ Sam Eldessouky
      Name: Sam Eldessouky
      Title: Executive Vice President, Chief Financial Officer

     

    Date: June 18, 2025

     

     

    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    SEC Filings

    See more
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/18/25 4:52:57 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/10/25 9:05:43 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by Bausch + Lomb Corporation

      SD - Bausch & Lomb Corp (0001860742) (Filer)

      5/30/25 4:14:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Citigroup with a new price target

      Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

      12/11/24 7:25:38 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ("Notes"). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. As previously announced, the company is also seeking to partia

      6/18/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ("Notes"). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the "New Term B Loan Facility") and a new $800 million revolving credit facility (the

      6/10/25 8:48:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

      Blink Nourish and Blink Boost are now available at most U.S. national retailers, including Walmart, Target, CVS, Walgreens and Amazon Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film Blink Boost's formula is pH-balanced to match healthy tears, making it comfortable when applied Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to

      6/4/25 6:59:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care